Literature DB >> 21211603

Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.

Sergio Manzano-Fernández1, Thomas Mueller, Domingo Pascual-Figal, Quynh A Truong, James Louis Januzzi.   

Abstract

The aim of the present study was to determine whether the risk of mortality associated with the concentration of soluble ST2 (sST2) differs in patients with acutely decompensated heart failure with preserved ejection fraction (HFpEF) compared to patients with systolic heart failure. We prospectively enrolled 447 patients with acutely decompensated heart failure. Blood samples were collected at presentation to determine the sST2 concentration. HFpEF was defined as symptoms or signs of acutely decompensated heart failure and left ventricular ejection fraction of ≥50% on the echocardiogram. The patients were followed up for 1 year, and the vital status was obtained for all. The sST2 concentrations were greater in the patients with systolic heart failure (n = 250) than in those with HFpEF (n = 197) at 0.55 versus 0.38 ng/ml (p <0.001). Receiver operating characteristic curve analyses showed different cutoff point values for sST2 for the prediction of 1-year mortality in patients with HFpEF (>0.35 ng/ml) and systolic heart failure (>0.56 mg//ml). These cutoff points had similar prognostic accuracy (area under the curve of 0.69 vs 0.73; p >0.05). In the adjusted analyses that included amino terminal B-type natriuretic peptide concentrations, elevated sST2 concentrations were associated with a greater mortality risk in both populations (HFpEF, per ng/ml, hazard ratio 1.41, 95% confidence interval 1.14 to 1.76, p = 0.002; and systolic heart failure, per ng/ml, hazard ratio 1.20, 95% confidence interval 1.10 to 1.32, p <0.001). The determination of the sST2 concentration improved the clinical risk prediction compared to amino terminal B-type natriuretic peptide, as assessed by both the improved C-statistic and an improvement in the net reclassification index and integrated discrimination improvement analyses. In conclusion, in the present multicenter study, sST2 concentrations were lower in patients with HfpEF; however, sST2 remained an independent predictor of mortality, regardless of the left ventricular ejection fraction. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21211603      PMCID: PMC3218083          DOI: 10.1016/j.amjcard.2010.09.011

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

1.  Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.

Authors:  Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi
Journal:  Circ Heart Fail       Date:  2009-05-14       Impact factor: 8.790

2.  Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.

Authors:  Robin A P Weir; Ashley M Miller; Grace E J Murphy; Suzanne Clements; Tracey Steedman; John M C Connell; Iain B McInnes; Henry J Dargie; John J V McMurray
Journal:  J Am Coll Cardiol       Date:  2010-01-19       Impact factor: 24.094

3.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

4.  Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.

Authors:  Wilson S Colucci; Theodore J Kolias; Kirkwood F Adams; William F Armstrong; Jalal K Ghali; Stephen S Gottlieb; Barry Greenberg; Michael I Klibaner; Marrick L Kukin; Jennifer E Sugg
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

5.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.

Authors:  Domingo A Pascual-Figal; Jordi Ordoñez-Llanos; Pedro L Tornel; Rafael Vázquez; Teresa Puig; Mariano Valdés; Juan Cinca; Antoni Bayes de Luna; Antoni Bayes-Genis
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

6.  Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.

Authors:  Sergio Manzano-Fernández; Miguel Boronat-Garcia; María Dolores Albaladejo-Otón; Patricia Pastor; Iris Paula Garrido; Francisco Jose Pastor-Pérez; Pedro Martínez-Hernández; Mariano Valdés; Domingo Andres Pascual-Figal
Journal:  Am J Cardiol       Date:  2009-06-15       Impact factor: 2.778

7.  Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease.

Authors:  Abelardo Martinez-Rumayor; Carlos A Camargo; Sandy M Green; Aaron L Baggish; Michelle O'Donoghue; James L Januzzi
Journal:  Am J Clin Pathol       Date:  2008-10       Impact factor: 2.493

8.  Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.

Authors:  Shafiq U Rehman; Thomas Mueller; James L Januzzi
Journal:  J Am Coll Cardiol       Date:  2008-10-28       Impact factor: 24.094

9.  Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.

Authors:  Thomas Mueller; Benjamin Dieplinger; Alfons Gegenhuber; Werner Poelz; Richard Pacher; Meinhard Haltmayer
Journal:  Clin Chem       Date:  2008-04       Impact factor: 8.327

10.  Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling.

Authors:  Kenjiro Seki; Shoji Sanada; Anastacia Y Kudinova; Matthew L Steinhauser; Vandna Handa; Joseph Gannon; Richard T Lee
Journal:  Circ Heart Fail       Date:  2009-09-22       Impact factor: 8.790

View more
  66 in total

1.  Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.

Authors:  Jennifer E Ho; Wei-Yu Chen; Ming-Huei Chen; Martin G Larson; Elizabeth L McCabe; Susan Cheng; Anahita Ghorbani; Erin Coglianese; Valur Emilsson; Andrew D Johnson; Stefan Walter; Nora Franceschini; Christopher J O'Donnell; Abbas Dehghan; Chen Lu; Daniel Levy; Christopher Newton-Cheh; Honghuang Lin; Janine F Felix; Eric R Schreiter; Ramachandran S Vasan; James L Januzzi; Richard T Lee; Thomas J Wang
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 3.  Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2015-07

Review 4.  ST2 as a cardiovascular risk biomarker: from the bench to the bedside.

Authors:  James L Januzzi
Journal:  J Cardiovasc Transl Res       Date:  2013-04-05       Impact factor: 4.132

5.  Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.

Authors:  Michael R Zile; Pardeep S Jhund; Catalin F Baicu; Brian L Claggett; Burkert Pieske; Adriaan A Voors; Margaret F Prescott; Victor Shi; Martin Lefkowitz; John J V McMurray; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

Review 6.  Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.

Authors:  Jeremy Cypen; Tariq Ahmad; Jeffrey M Testani; Adam D DeVore
Journal:  Curr Heart Fail Rep       Date:  2017-10

7.  Red cell distribution width predicts mid-term prognosis in patients hospitalized with acute heart failure: the RDW in Acute Heart Failure (RE-AHF) study.

Authors:  Remo Melchio; Gianluca Rinaldi; Elisa Testa; Alessia Giraudo; Cristina Serraino; Christian Bracco; Laura Spadafora; Andrea Falcetta; Stefano Leccardi; Alberto Silvestri; Luigi Fenoglio
Journal:  Intern Emerg Med       Date:  2018-10-01       Impact factor: 3.397

8.  Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.

Authors:  Erin E Coglianese; Martin G Larson; Ramachandran S Vasan; Jennifer E Ho; Anahita Ghorbani; Elizabeth L McCabe; Susan Cheng; Michael G Fradley; Dana Kretschman; Wei Gao; George O'Connor; Thomas J Wang; James L Januzzi
Journal:  Clin Chem       Date:  2012-10-11       Impact factor: 8.327

9.  Soluble ST2 predicts elevated SBP in the community.

Authors:  Jennifer E Ho; Martin G Larson; Anahita Ghorbani; Susan Cheng; Ramachandran S Vasan; Thomas J Wang; James L Januzzi
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

Review 10.  Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.

Authors:  Michael R Zile; Catalin F Baicu
Journal:  J Cardiovasc Transl Res       Date:  2013-05-29       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.